Prosensa and GlaxoSmithKline expand Duchenne dystrophy alliance


Leiden - Prosensa NV and British drugmaker GlaxoSmithKline have expanded their cooperation concerning RNA-modulating drugs against Duchenne muscular dystrophy (DMD). Two programmes, covering 4 drug new drug candidates for specific patient subpopulations, have been added to the existing collaboration in DMD. According to the terms of the agreement, GSK has paid two upfront fees and will add milestones dependant on research progress. Within the new programmes, Prosensa and GSK will focus on the skipping of four exons (exon 45, 52, 53, and 55), in addition to their existing programmes that target skipping of exon 51 and 44 (PRO051/GSK2402968 and PRO044). GSK has an option to select two of these additional four compounds for later-stage development and commercialization. Prosensa will retain certain limited European commercialisation rights alongside GSK for the two compounds selected by GSK. For the two compounds not selected by GSK, Prosensa will retain full commercialization rights.



Paris/Gosselies – Biotech cluster Lyonbiopôle in the Rhône-Alpes region and Biowin, which is based in the French-speaking part of Belgium, have laid the foundations for a transborder cluster. “From the outset, we wanted to adopt...



Amsterdam – Dutch specialty pharmaceutical company Spe­Pharm (Amsterdam) has secured funds worth €26m after entering into a €10m revenue interest acquisition financing agreement with Paul Capital Healthcare. The cash injection...



Ghent – BASF Plant Science and the Flanders Institute for Biotechnology (VIB) have signed a major cooperation agreement on research into plant genetic mechanisms to increase yield and improve tolerance to environmental stress...



Brussels – The 21 research groups and five SMEs that make up the new EU-funded LipidomicNet project have launched a knowledge platform on Wikipedia ( The novel resource, which will be regularly updated by...



Luxembourg – The government of Luxembourg has tapped three prominent US biomedical science organisations to accelerate the country’s pace of innovation in the biosciences by developing a biobank, to conduct two major projects to...



Ghent – Belgian researchers under Freddy Haesebrouck have for the first time cultured the animal pathogen Helicobacter suis, which causes deadly stomach ulcers in pigs. Because the new species is related to the human pathogen...



Professor Erik De Clercq (University of Leuven, Belgium) has received the European Inventor of the Year 2008 award. De Clercq pioneered the use of nucleotide analogues to treat viral infections causing herpes, hepatitis B and...



In a Phase III study, Pharming Group N.V.’s (Leiden) recombinant human C1 inhibitor Rhucin® met the primary and secondary endpoints of safety and efficacy as acute treatment for hereditary angioedema (HAE). Patients who received...



Amsterdam – In order to enhance the valorisation of academic results, the Netherlands Genomics Initiative (NGI) is now supporting the foundation of new companies. Teams of researchers and entrepreneurs from all of the NGI’s...



Ghent – Pronota NV, a biomarker specialist firm that is based in Belgium, has launched its protein biomarker verification platform MASSterclass™. Pronota says that the novel antibody-free system will help to reduce the cost and...

Displaying results 151 to 160 out of 304

< Previous 151-160 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week


Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...


All Events



BioVaria 2015

Stock list

All quotes


  • CYTOS1.32 CHF30.69%
  • WILEX5.08 EUR17.32%
  • SYNGENTA339.90 CHF8.11%


  • THERAMETRICS0.07 CHF-12.50%
  • MEDIGENE10.26 EUR-6.39%
  • MOLOGEN4.85 EUR-1.82%


  • 4SC5.20 EUR306.2%
  • WILEX5.08 EUR77.6%
  • PAION2.86 EUR21.7%


  • BIOTEST71.20 EUR-26.7%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.26 EUR-16.8%


  • SANTHERA98.00 CHF2412.8%
  • CYTOS1.32 CHF676.5%
  • WILEX5.08 EUR497.6%


  • MOLOGEN4.85 EUR-55.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.30 EUR-27.9%

No liability assumed, Date: 05.05.2015

Current issue

All issues